MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$22,491,000
EPS
-$0.28
Unit: Dollar
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
-
-
0*
-
Research and development
16,172,000
13,397,977
10,402,327*
8,970,010
General and administrative
7,205,000
6,599,759
4,934,491*
3,708,959
Total operating expenses
23,377,000
19,997,736
15,336,818*
12,678,969
Loss from operations
-23,377,000
-19,997,736
-15,336,818*
-12,678,969
Changes in fair value of warrant liabilities
1,111,000
482,474
24,822,933*
-61,598,908
Interest expense
62,000
62,745
79,208.5*
43,292
Interest income
1,709,000
1,047,197
428,839.5*
655,233
Other income, net
350,000
626,873
1,541,517.5*
765,881
Warrant issuance cost
-
-
-
4,852,292
Warrant issuance expense
-
-
1,213,073*
-
Total other income (expense)
886,000
1,128,851
-24,144,857.5*
58,124,438
Net gain
-22,491,000
-18,868,885
-39,481,675.5*
45,445,469
Unrealized gain, change in fair value of available-for-sale securities, net of tax
-
-
46,366*
-
Foreign currency translation gain (loss)
-
-
34,114*
-
Total comprehensive income (loss)
-
-
-39,401,195.5
-
Basic EPS
-0.28
-0.35
-1.037
0.5
Diluted EPS
-0.28
-0.35
-0.642
-0.21
Basic Average Shares
79,753,100
53,558,639
37,980,425
10,660,500
Diluted Average Shares
79,753,100
53,558,639
61,340,193*
77,863,263
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Interest income$1,709,000 (12501.39%↑ Y/Y)Other income, net$350,000 (18.39%↑ Y/Y)Net gain-$22,491,000 (-122.37%↓ Y/Y)Total other income(expense)$886,000 (331.81%↑ Y/Y)Changes in fair value ofwarrant liabilities$1,111,000 (77.18%↑ Y/Y)Interest expense$62,000 (-3.64%↓ Y/Y)Loss from operations-$23,377,000 (-140.21%↓ Y/Y)Total operatingexpenses$23,377,000 (140.21%↑ Y/Y)Research and development$16,172,000 (131.14%↑ Y/Y)General andadministrative$7,205,000 (163.40%↑ Y/Y)

SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics, Inc. (SABS)